Skip to main content

Table 2 Safety

From: Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

 

Grade 1–2

Grade 3–4

On Pz (No.)

NO Pz (No.)

Total (No.)

On Pz (No.)

NO Pz (No.)

Total (No.)

Hematologic

 Anemia

3

1

4

 Neutropenia

1

1

 Thrombocytopenia

1

1

2

Non-hematologic

 Diarrhea

3

 

3

1

 

1

 Pneumonitis

1

 

1

1

 

1

 Rash

3

1

4

 Hypothyroidism

6

2

8

 LFTs

8

2

10

3

 

3

  1. Toxicity was graded as per NCI CTCAE v4.0
  2. Pz pazopanib, 400–800 mg po daily; LFTs liver function tests abnormalities